Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.

@article{Jungwirth1997InhibitionOI,
  title={Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.},
  author={Andreas Jungwirth and Andrew V. Schally and Jacek Pinski and G{\'a}bor Halmos and Kate Groot and Patricia Armatis and Manuel Vadillo-Buenfil},
  journal={British Journal of Cancer},
  year={1997},
  volume={75},
  pages={1585 - 1592}
}
Tumour-inhibitory effects of a new antagonist of growth hormone-releasing hormone (GH-RH), MZ-4-71, were evaluated in nude mice bearing androgen-independent human prostate cancer cell lines DU-145 and PC-3 and in Copenhagen rats implanted with Dunning R-3327 AT-1 prostatic adenocarcinoma. After 6 weeks of therapy, the tumour volume in nude mice with DU-145 prostate cancers treated with 40 microg day(-1) MZ-4-71 was significantly decreased to 37 +/- 13 mm3 (P < 0.01) compared with controls that… 
Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers
TLDR
It is demonstrated that GHRH antagonists inhibit androgens-independent prostate cancers and, after combination with androgen deprivation, also androgen-sensitive tumors and the therapy with G HRH antagonist could be considered for the management of both androgen -dependent or - independent prostate cancers.
Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.
TLDR
The results indicate that GHRH antagonists can reduce the growth of human endometrial cancer and could be used as an alternative adjuvant therapy for the management of endometricrial cancer.
Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice.
TLDR
The results suggest that GH-RH antagonists MZ-5-156 and JV-1 -36 inhibit the growth of U-87MG human glioblastoma by mechanisms that involve the suppression of IGF system.
Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice
TLDR
The results suggest that GH-RH antagonists inhibit MDA-MB-468 breast cancers possibly through mechanisms involving interference with locally produced GH- RH.
Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel
TLDR
The results demonstrate that GHRH antagonists might provide a therapy for breast cancer and could be combined with docetaxel chemotherapy to enhance the efficacy of treatment.
Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma.
TLDR
GH-RH may be an autocrine growth factor for H838 NSCLC and a new approach to the treatment of this malignancy based on the use of antagonistic analogues of GH-RH.
Carcinoma the Proliferation of Experimental Non-Small Cell Lung Antagonists of Growth Hormone-Releasing Hormone Inhibit
TLDR
The results extend the findings on the involvement of IGF-I in NSCLC and suggest that GH-RH may be an autocrine growth factor for H838NSCLC.
Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone.
  • H. Kiaris, A. V. Schally
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 1999
TLDR
The findings suggest that tumor inhibition induced by the GH-RH antagonists in U-87MG glioblastomas is associated with the down-regulation of the hTRT gene, resulting in a decrease in telomerase activity.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 46 REFERENCES
Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH).
TLDR
It is demonstrated that the GHRH antagonists Mz-4-71 and MZ-5-156 can inhibit the growth of SCLC and NSCLC, a new approach to the management of lung cancer merits further investigation.
Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone.
TLDR
It is demonstrated that the GH-RH antagonist MZ-4-71 can significantly inhibit the growth of SK-ES-1 and MNNG/HOS osteosarcomas in mice.
The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors.
TLDR
The results might indicate that estrone and progesterone treatment stimulated growth of hormone-dependent GR mouse mammary tumors mainly by an increase of growth fraction and cell production rate.
Insulin‐like growth factor I: Action and receptor characterization in human prostate cancer cell lines
TLDR
The results suggest that IGF‐I may play an important role in stimulating the growth and progression of prostate cancer.
Growth hormone receptor expression in the dunning R 3327 prostatic carcinoma of the rat
TLDR
The presence of GH‐R receptors in proliferating prostatic tumor cells supports the concept that GH reacts directly on prostate target tissue to facilitate tumor cell growth.
Growth hormone directly affects the function of the different lobes of the rat prostate.
TLDR
It is suggested that GH might either potentiate the action of androgens on the prostate or act directly on this gland by a mechanism that does not depend on testicular androgens.
Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for an IGF-II autocrine growth loop.
TLDR
The data suggest IGF- II is as an autocrine growth factor in DU145 cells, and that inhibition of IGF-II-dependent growth of human prostate cancer cells may represent a new therapeutic strategy for this disease.
Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3).
TLDR
IG-II is involved in the autocrine control of PC-3 cell proliferation via the type 1 IGF receptor and this proliferation is directly dependent on IGF-II bioavailability that itself is modulated by the limited IGFBP-3 proteolysis induced, at least in part, by urokinase-type plasminogen activator and plAsmin.
Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
TLDR
It is demonstrated that bombesin/GRP antagonist RC-3095 and somatostatin analogues such as RC-160 can inhibit the growth of human glioblastoma cell lines U-87MG and U-373MG in vitro as well as in vivo.
Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT.
TLDR
The Dunning R-3327-H is a well-differentiated transplantable rat prostatic adenocarcinoma that contains both hormone-sensitive and -insensitive cells that has been permitted to grow in a castrated male, and a new slow-growing, well- differentiated hormone-insensitive subline of the tumor has been established.
...
1
2
3
4
5
...